Erste Group Bank Has Weak Outlook for AbbVie FY2026 Earnings

AbbVie Inc. (NYSE:ABBV) – Stock analysts at Erste Group Bank lowered their FY2026 earnings estimates for shares of AbbVie in a report issued on Wednesday, October 21st. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of $13.90 for the year, down from their prior forecast of $14.00. Erste Group Bank currently has a “Buy” rating on the stock. The consensus estimate for AbbVie’s current full-year earnings is $13.94 per share.

Other analysts have also issued research reports about the stock. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. Cantor Fitzgerald increased their price target on AbbVie from $285.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, October 8th. Weiss Ratings upgraded AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. JPMorgan Chase & Co. raised their price target on AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a research report on Thursday, October 8th. Finally, Wells Fargo & Company lifted their price objective on AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $278.07.

AbbVie Stock Down 0.1%

Shares of ABBV opened at $284.59 on Friday. The stock’s fifty day simple moving average is $265.60 and its 200-day simple moving average is $241.46. The firm has a market capitalization of $502.80 billion, a PE ratio of 80.39, a price-to-earnings-growth ratio of 1.30 and a beta of 0.24. AbbVie has a 12-month low of $190.75 and a 12-month high of $291.40.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period last year, the company posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS.

Hedge Funds Weigh In On AbbVie

A number of hedge funds and other institutional investors have recently bought and sold shares of ABBV. Ranch Capital Advisors Inc. raised its stake in AbbVie by 37.0% during the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after buying an additional 4,017 shares during the period. Capital Advisors Inc. OK boosted its holdings in AbbVie by 11.2% in the second quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock worth $112,516,000 after acquiring an additional 45,132 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab acquired a new stake in AbbVie in the second quarter valued at approximately $23,557,000. Wedge Capital Management L L P NC grew its stake in AbbVie by 7.5% in the second quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock valued at $33,865,000 after acquiring an additional 9,380 shares during the period. Finally, State Street Corp increased its holdings in shares of AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after acquiring an additional 1,379,232 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.06% of the company’s stock.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. AbbVie’s dividend payout ratio (DPR) is 195.48%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported that its investigational lutikizumab met the primary endpoint and eight ranked secondary endpoints in the Phase 3 INTREPID trial for moderate-to-severe hidradenitis suppurativa. The drug improved disease symptoms, reduced flares and was generally well tolerated, supporting the company’s effort to expand its immunology pipeline. AbbVie Announces INTREPID Trial Results
• Positive Sentiment: Investors continue to point to strong growth from Skyrizi and Rinvoq, progress in oncology and potential successors to key immunology products. Recent Crohn’s disease data and an eczema candidate could help AbbVie manage future patent expirations and support longer-term revenue growth. Great News for AbbVie Stock Investors
• Neutral Sentiment: Wall Street brokers broadly rate ABBV as a Buy, while income investors value its long record of annual dividend increases. However, higher interest rates can make high-yield alternatives more competitive and may limit valuation expansion. What Higher Interest Rates Mean for Dividend Stocks
• Negative Sentiment: Although lutikizumab technically met the INTREPID trial goals, analysts characterized the efficacy as below expectations, with the advantage over placebo viewed as underwhelming. That raises questions about the drug’s commercial potential and allowed rival MoonLake’s shares to benefit. Lutikizumab Phase 3 Results
• Negative Sentiment: AbbVie also halted an early-stage liver-cancer combination trial, adding a setback to its oncology pipeline. With the stock near its 52-week high and patent cliffs approaching, investors may demand strong earnings and clear replacement-product progress to justify the valuation. AbbVie Halts Liver Cancer Trial

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.